The new possibilities offered by intraoperative PET/CT imaging, coupled with the specificity of PSMA molecular targeting, hold great potential for improving the staging accuracy and guiding robot-assisted radical prostatectomy (RARP) and pelvic lymph node dissection (PLND) in prostate cancer patients. This evidence concerns the gene FOLH1 and Familial prostate cancer.